The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Partial and Generalized Lipodystrophy: Comparison of Baseline Characteristics and Response to Metreleptin
Open accessAbstract
CONTEXT: Lipodystrophies are extreme forms of metabolic syndrome. Metreleptin was approved in the United States for generalized lipodystrophy (GLD) but not partial lipodystrophy (PLD). OBJECTIVE: The objective of the study was to test metreleptin's efficacy in PLD vs GLD and find predictors for treatment response. DESIGN: This was a prospective, single-arm, open-label study since 2000 with continuous enrollment. Current analysis included metreleptin treatment for 6 months or longer as of January 2014. SETTING: The study was conducted at the National Institutes of Health (Bethesda, Maryland). PARTICIPANTS: Patients clinically diagnosed with lipodystrophy, leptin less than 8 ng/mL (males) or less than 12 (females), age older than 6 months, and one or more metabolic abnormalities (diabetes, insulin resistance, or hypertriglyceridemia) participated in the study. INTERVENTION: The interventions included sc metreleptin injections (0.06-0.24 mg/kg · d). MAIN OUTCOMES AND MEASURES: Changes in glycated hemoglobin A1c (HbA1c) and triglycerides after 6 and 12 months of metreleptin were measured. RESULTS: Baseline metabolic parameters were similar in 55 GLD [HbA1c 8.4% ± 2.3%; triglycerides, geometric mean (25th, 75th percentile), 467 mg/dL (200, 847)] and 31 PLD patients [HbA1c 8.1% ± 2.2%, triglycerides 483 mg/dL (232, 856)] despite different body fat and endogenous leptin. At 12 months, metreleptin decreased HbA1c (to 6.4% ± 1.5%, GLD, P < .001; 7.3% ± 1.6%, PLD, P = .004) and triglycerides [to 180 mg/dL (106, 312), GLD, P < .001; 326 mg/dL (175, 478), PLD, P = .02]. HbA1c and triglyceride changes over time significantly differed between GLD and PLD. In subgroup analyses, metreleptin improved HbA1c and triglycerides in all GLD subgroups except those with baseline triglycerides less than 300 mg/dL and all PLD subgroups except baseline triglycerides less than 500 mg/dL, HbA1c less than 8%, or endogenous leptin greater than 4 ng/mL. CONCLUSIONS: In addition to its proven efficacy in GLD, metreleptin is effective in selected PLD patients with severe metabolic derangements or low leptin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247 · cited 1×
“Studies conducted at the National Institutes of Health (NIH) Clinical Center showed that metreleptin treatment reduced food intake (13) and substantially improved most metabolic abnormalities in lipodystrophy patients, studied as a cohort of all forms with no distinction between lipodystrophy subtypes (14, 15).”
BackgroundStandards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., & Goldstein, J. L. (1999) · Nature · doi:10.1038/43448 · Cited by 1,038 · cited 1×
“Leptin administration in a mouse model of GLD was a turning point in lipodystrophy management (12).”
BackgroundLong-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy
Javor, E. D., Cochran, E. K., Musso, C., Young, J. R., DePaoli, A. M., & Gorden, P. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1994 · Cited by 226
Self-citationMoon, H.-S., Matarese, G., Brennan, A. M., Chamberland, J. P., Liu, X., Fiorenza, C. G., Mylvaganam, G. H., Abanni, L., Carbone, F., Williams, C. J., et al. (2011) · Diabetes · doi:10.2337/db10-1791 · Cited by 151 · cited 1×
“Meterleptin has not been effective in reducing insulin resistance in obese subjects with type 2 diabetes (28), likely due to insensitivity to added, recombinant leptin in patients with already high endogenous leptin produced by large adipose tissue depots.”
BackgroundMusso, C., Cochran, E., Javor, E., Young, J., DePaoli, A. M., & Gorden, P. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.021 · Cited by 146
Self-citationMcDuffie, J. R., Riggs, P. A., Calis, K. A., Freedman, R. J., Oral, E. A., DePaoli, A. M., & Yanovski, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031868 · Cited by 129 · cited 2×
“Studies conducted at the National Institutes of Health (NIH) Clinical Center showed that metreleptin treatment reduced food intake (13) and substantially improved most metabolic abnormalities in lipodystrophy patients, studied as a cohort of all forms with no distinction between lipodystrophy subtypes (14, 15).”
BackgroundJavor, E. D., Moran, S. A., Young, J. R., Cochran, E. K., DePaoli, A. M., Oral, E. A., Turman, M. A., Blackett, P. R., Savage, D. B., O’Rahilly, S., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032140 · Cited by 114
Self-citation
Cited by
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Brown, R. J., Araujo-Vilar, D., Cheung, P. T., Dunger, D., Garg, A., Jack, M., Mungai, L., Oral, E. A., Patni, N., Rother, K. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2466 · Cited by 529
Self-citationFriedman, J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci91578 · Cited by 270
Congenital generalized lipodystrophies—new insights into metabolic dysfunction
Patni, N., & Garg, A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.123 · Cited by 261
Diagnosis and treatment of lipodystrophy: a step-by-step approach
Araújo-Vilar, D., & Santini, F. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0887-z · Cited by 194
Chait, A., & Eckel, R. H. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0203 · Cited by 128
Metadata
- Authors
- Diker-Cohen, T., Cochran, E., Gorden, P., & Brown, R. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-05
- Volume
- 100
- Issue
- 5
- Pages
- 1802-1810
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2154029700
- Cited by
- 178
- References
- 8
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Partial and Generalized Lipodystrophy: Comparison of Baseline Characteristics and Response to Metreleptin. https://app.cochat.ai/papers/10.1210/jc.2014-4491
- The paper
- Diker-Cohen, T., Cochran, E., Gorden, P., & Brown, R. J. (2015). Partial and Generalized Lipodystrophy: Comparison of Baseline Characteristics and Response to Metreleptin. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2014-4491
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.